HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas
Introduction: Gastric cancer is one of the leading causes of cancer mortality in the world/India with majority being diagnosed at an advanced stage. Various chemotherapeutic regimens have modestly improved overall survival leading to quest for novel therapeutic agents. Overexpression of HER2 in...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2015-03-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/5630/12581_CE(Ra1)_F(GH)_PF1(PAK)_PFA(P)_PF2(PAG).pdf |
| _version_ | 1811285868318556160 |
|---|---|
| author | Indu Rajagopal S R Niveditha R Sahadev Preethan Kamagere Nagappa Sowmya Goddanakoppal Rajendra |
| author_facet | Indu Rajagopal S R Niveditha R Sahadev Preethan Kamagere Nagappa Sowmya Goddanakoppal Rajendra |
| author_sort | Indu Rajagopal |
| collection | DOAJ |
| description | Introduction: Gastric cancer is one of the leading causes
of cancer mortality in the world/India with majority being
diagnosed at an advanced stage. Various chemotherapeutic
regimens have modestly improved overall survival leading to
quest for novel therapeutic agents. Overexpression of HER2 in
many gastric cancers has lead to the advent of targeted therapy
with anti HER2 antibody like Trastusumab which has improved
the overall survival.
Materials and Methods:Sixty cases of gastric adenocarcinomas
(44 biopsies and 16 gastrectomies) over the past five years ( June
2009 to June 2014),were included in the study. Diagnosis was
confirmed by review of slides and IHC with anti HER2 antibodies
was performed using Dako Real Envision Detection system and
scoring was done by Hoffmann et al., scoring system.
Results: Of the 60 cases, majority were males (60%),with a
mean age of 65.65 yrs. Tumours in antrum (76.7%) formed
the major bulk. HER2 expression was observed in 26.7% of
Tumours, predominantly in males (p=0.006) and intestinal type
(p= 0.054). HER2 expression correlated with Tumour grade
(moderately differentiated and well differentiated, p= 0.042).
Tumours of gastro-esophageal junction (GEJ) showed HER2
expression in 45.5% as opposed to 22.4% in gastric location.
Poorly differentiated and diffuse type of adenocarcinomas did
not express HER2. Two of three Tumours from patients in the age
group 31-40 y expressed HER2.
Conclusion: Male gender, intestinal-type and moderately differentiated gastric cancers may be the ones that can be targeted
for therapy using Herceptin. Though trastusumab is approved
for advanced gastric and GEJ cancers, it’s role in adjuvant /
neo-adjuvant setting in early stages needs to be evaluated
with newer agents like Pertuzumab, Bevacizumab, especially
in young patients. |
| first_indexed | 2024-04-13T02:51:17Z |
| format | Article |
| id | doaj.art-690e8242591a42c9b740d02ec9df0404 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-04-13T02:51:17Z |
| publishDate | 2015-03-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-690e8242591a42c9b740d02ec9df04042022-12-22T03:05:50ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2015-03-0193EC06EC1010.7860/JCDR/2015/12581.5630HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) AdenocarcinomasIndu Rajagopal0S R Niveditha1R Sahadev2Preethan Kamagere Nagappa3Sowmya Goddanakoppal Rajendra4Post Graduate, Department of Pathology, Kempegowda Institute of Medical Sciences, Karnataka, India.Professor, Department of Pathology, Kempegowda Institute of Medical Sciences, Karnataka, India.Professor and HOD, Department of Surgical Gastroenterology, Kempegowda Institute of Medical Sciences, Karnataka, India.Associate Professor, Department of Surgical Gastroenterology, Kempegowda Institute of Medical Sciences, Karnataka, India.Senior Resident, Department of Surgical Gastroenterology, Kempegowda Institute of Medical Sciences, Karnataka, India.Introduction: Gastric cancer is one of the leading causes of cancer mortality in the world/India with majority being diagnosed at an advanced stage. Various chemotherapeutic regimens have modestly improved overall survival leading to quest for novel therapeutic agents. Overexpression of HER2 in many gastric cancers has lead to the advent of targeted therapy with anti HER2 antibody like Trastusumab which has improved the overall survival. Materials and Methods:Sixty cases of gastric adenocarcinomas (44 biopsies and 16 gastrectomies) over the past five years ( June 2009 to June 2014),were included in the study. Diagnosis was confirmed by review of slides and IHC with anti HER2 antibodies was performed using Dako Real Envision Detection system and scoring was done by Hoffmann et al., scoring system. Results: Of the 60 cases, majority were males (60%),with a mean age of 65.65 yrs. Tumours in antrum (76.7%) formed the major bulk. HER2 expression was observed in 26.7% of Tumours, predominantly in males (p=0.006) and intestinal type (p= 0.054). HER2 expression correlated with Tumour grade (moderately differentiated and well differentiated, p= 0.042). Tumours of gastro-esophageal junction (GEJ) showed HER2 expression in 45.5% as opposed to 22.4% in gastric location. Poorly differentiated and diffuse type of adenocarcinomas did not express HER2. Two of three Tumours from patients in the age group 31-40 y expressed HER2. Conclusion: Male gender, intestinal-type and moderately differentiated gastric cancers may be the ones that can be targeted for therapy using Herceptin. Though trastusumab is approved for advanced gastric and GEJ cancers, it’s role in adjuvant / neo-adjuvant setting in early stages needs to be evaluated with newer agents like Pertuzumab, Bevacizumab, especially in young patients.https://jcdr.net/articles/PDF/5630/12581_CE(Ra1)_F(GH)_PF1(PAK)_PFA(P)_PF2(PAG).pdfgastric / gej adenocarcinomaher2/ neuimmunohistochemistry (ihc) |
| spellingShingle | Indu Rajagopal S R Niveditha R Sahadev Preethan Kamagere Nagappa Sowmya Goddanakoppal Rajendra HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas Journal of Clinical and Diagnostic Research gastric / gej adenocarcinoma her2/ neu immunohistochemistry (ihc) |
| title | HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas |
| title_full | HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas |
| title_fullStr | HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas |
| title_full_unstemmed | HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas |
| title_short | HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas |
| title_sort | her 2 expression in gastric and gastro esophageal junction gej adenocarcinomas |
| topic | gastric / gej adenocarcinoma her2/ neu immunohistochemistry (ihc) |
| url | https://jcdr.net/articles/PDF/5630/12581_CE(Ra1)_F(GH)_PF1(PAK)_PFA(P)_PF2(PAG).pdf |
| work_keys_str_mv | AT indurajagopal her2expressioningastricandgastroesophagealjunctiongejadenocarcinomas AT srniveditha her2expressioningastricandgastroesophagealjunctiongejadenocarcinomas AT rsahadev her2expressioningastricandgastroesophagealjunctiongejadenocarcinomas AT preethankamagerenagappa her2expressioningastricandgastroesophagealjunctiongejadenocarcinomas AT sowmyagoddanakoppalrajendra her2expressioningastricandgastroesophagealjunctiongejadenocarcinomas |